BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating

BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating

BioLife Solutions, Inc. (NASDAQ: BLFS) has received a significant boost in its stock valuation, as H.C. Wainwright analyst Patrick Trucchio raised the price target to $32 from $28, while maintaining a Buy rating. This positive move by the analyst comes after a series of encouraging developments for the biopharmaceutical company.

The new price target reflects the analyst's confidence in BioLife's lead product candidate, which is an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome. The strong performance of BioLife's lead product has been a key driver for the company's growth, as evidenced by its recent quarterly earnings report.

BioLife reported its Q2 2025 earnings on August 6, showing an earnings per share (EPS) of -$0.12, significantly beating the forecasted -$0.33. Revenue came in at $127.78 million, surpassing expectations of $107.36 million, marking a 19.02% surprise. Following the announcement, BioLife's stock rose by 2.99% in aftermarket trading, closing at $53.39 [3].

The analyst's optimism is also supported by BioLife's robust performance in Q2 2025, with a strong year-over-year revenue growth of 64%. This growth was driven by the success of BioLife's lead product, particularly in treating Alagille syndrome and PFIC. The company also highlighted its positive operating cash flow and a cash contribution margin exceeding 50%.

Additionally, BioLife has been receiving strong analyst support. Eight research firms have given the stock an average "Buy" recommendation, with a consensus target price of $28. Several analysts have reaffirmed their positive outlook on BioLife, including Evercore ISI, JMP Securities, and Raymond James Financial [1].

BioLife's strong financial performance and analyst support have led to a significant increase in its market capitalization. The company's market cap stands at $2.64 billion, with the stock currently trading near its 52-week high of $54.78.

In conclusion, BioLife Pharmaceuticals' recent earnings report and analyst upgrades reflect the company's strong performance and growth prospects. The new price target from H.C. Wainwright is a testament to the analyst's confidence in BioLife's future, particularly its lead product candidate.

References:
[1] https://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-inc-nasdaqmirm-receives-consensus-recommendation-of-buy-from-analysts-2025-07-28/
[2] https://www.ainvest.com/news/wainwright-raises-price-target-atai-life-sciences-15-2508/
[3] https://www.investing.com/news/transcripts/earnings-call-transcript-mirum-pharmaceuticals-sees-revenue-boost-in-q2-2025-93CH-4175140